TRIOSTAT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Triostat, and what generic alternatives are available?
Triostat is a drug marketed by Endo Operations and is included in one NDA.
The generic ingredient in TRIOSTAT is liothyronine sodium. There are four drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the liothyronine sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Triostat
A generic version of TRIOSTAT was approved as liothyronine sodium by XGEN PHARMS on August 17th, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRIOSTAT?
- What are the global sales for TRIOSTAT?
- What is Average Wholesale Price for TRIOSTAT?
Summary for TRIOSTAT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 76 |
| Clinical Trials: | 2 |
| Patent Applications: | 1,189 |
| Drug Prices: | Drug price information for TRIOSTAT |
| What excipients (inactive ingredients) are in TRIOSTAT? | TRIOSTAT excipients list |
| DailyMed Link: | TRIOSTAT at DailyMed |
Recent Clinical Trials for TRIOSTAT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Seattle Children's Hospital | Phase 3 |
| Michael Portman | Phase 3 |
US Patents and Regulatory Information for TRIOSTAT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Operations | TRIOSTAT | liothyronine sodium | INJECTABLE;INJECTION | 020105-001 | Dec 31, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
